Taltz® (Ixekizumab)

Para consultar la información para prescribir completa de Taltz® (Ixekizumab) de clic en el siguiente enlace: Información para prescribir

La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.

How long after stopping ixekizumab before psoriasis relapses?

For ixekizumab responders at week 12 who were rerandomized to treatment withdrawal (ie, placebo), the median time to relapse was 164 days.

MX_cFAQ_IXE315_SYMPTOM_RETURN_AFTER_STOP_TREATMENT_PSORIASIS
MX_cFAQ_IXE315_SYMPTOM_RETURN_AFTER_STOP_TREATMENT_PSORIASIS
es-MX

Relapse of Psoriasis Following Ixekizumab Treatment Discontinuation

This medical response may not completely match the information in the current local labeling for IXEKIZUMAB. Please see local labeling for approved label information.

For the analyses summarized below, response was defined as a static Physician Global Assessment (sPGA) score of 0 (clear skin) or 1 (minimal) and relapse was defined as a sPGA score of ≥3.1

In 2 phase 3 clinical trials (UNCOVER-1 and -2), patients who were originally randomized to ixekizumab and who responded to treatment at week 12 were rerandomized to an additional 48 weeks of ixekizumab 80 mg every 4 weeks, ixekizumab 80 mg every 12 weeks, or placebo.1

In those week 12 responders to ixekizumab who were rerandomized to treatment withdrawal (ie, placebo), 7% maintained their clinical response at week 60.1 The median time to relapse was 164 days.2

In responders who were rerandomized to treatment with ixekizumab every 4 weeks, 73.8% maintained their response at week 60.1

References

1Gordon KB, Blauvelt A, Papp KA, et al; UNCOVER-1, UNCOVER-2, and UNCOVER-3 Study Groups. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345-356. http://dx.doi.org/10.1056/NEJMoa1512711

2Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Fecha de la última revisión: 2021 M07 26


Contáctenos para saber más de la información Médica de Lilly

Contacto vía correo electrónico

Correo electrónico: infomed@lilly.com

Envíe su consulta

Escriba su consulta